Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | $48.2M | $72.2M | $101.0M | $94.9M | $124.1M | $97.5M | $90.7M | $109.6M | $135.1M | $162.4M | $182.0M | $128.6M | $196.8M | $228.9M | $240.3M | $296.6M | $406.9M | $752.3M | $734.0M | $676.0M |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, West Pharmaceutical Services, Inc.'s last 12-month Operating Income is $575.8M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, West Pharmaceutical Services, Inc.'s Operating Income growth was (6.2%). The average annual Operating Income growth rates for West Pharmaceutical Services, Inc. have been 5.2% over the past three years, 15.2% over the past five years.